Nilotinib, a second-generation BCR::ABL1 inhibitor, significantly improves clinical outcomes in imatinib-resistant or intolerant CML patients and is recommended as first-line therapy for intermediate-to high-risk CML by the NCCN (2024) (Shah et al., 2024). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.